I'm LongbridgeAI, I can summarize articles.Jupiter Neurosciences pre-market down 8.33%; WF pre-market down 7.98%; ARTIUS II ACQUISITION INC COM USD0.0001 CL A (SUB/RIGHTS) 27/11/29 pre-market up 1011.11%; Weibus pre-market up 191.69%; Capricor Therapeutics pre-market up 98.34%
Pre-market Hot Trades in US Stocks
Jupiter Neurosciences, down 8.33% pre-market, has no significant news recently. Trading is active, with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
WF, down 7.98% pre-market, has no significant news recently. Trading is active, with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Top Gainers in Pre-market US Stocks
ARTIUS II ACQUISITION INC COM USD0.0001 CL A (SUB/RIGHTS) 27/11/29, up 1011.11% pre-market, has no significant news recently. Trading is active, with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Weibasi, up 191.69% pre-market. Based on recent key news:
-
On August 10, Wetour Robotics Ltd. released original content through the EDGAR system, disclosing the company's latest business developments. This announcement sparked positive market expectations for the company's future growth potential, driving the stock price significantly higher.
-
On August 11, the market showed extremely low tolerance for traditional business models, and investors expressed concerns about the company's ability to achieve digital integration. However, Wetour Robotics Ltd.'s announcement alleviated some concerns, further boosting the stock price.
-
No other significant news recently. The market shows extremely low tolerance for traditional business models, and investors are focused on digital integration.
Capricor Therapeutics, up 98.34% pre-market. Based on recent key news:
-
On August 14, Capricor Therapeutics announced that the US FDA agreed to review new data for its Duchenne muscular dystrophy treatment drug deramiocel. The company plans to submit additional trial data showing improvements in upper limb muscle function. The FDA's decision is seen as an unexpectedly positive signal, reducing regulatory risks and driving the stock price up 116.9%.
-
On August 14, Capricor Therapeutics reported a net loss of $40.7 million for the second quarter, with a loss of $0.70 per share. Despite poor financial performance, the company has $237.9 million in cash reserves and is waiting for regulatory clarity before commercial promotion. The stock price surged significantly in pre-market trading.
-
On August 14, analysts rated Capricor Therapeutics as "Hold," with no "Buy" or "Strong Buy" ratings. Wall Street's 12-month target price for the company is $5.00, approximately 19.3% higher than the closing price of $4.19 on August 12. The biotechnology sector has shown volatility recently, with increased regulatory risks